Pharming Group N.V. (AMS:PHARM) Leiden, The Netherlands, September 17, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it will present at the UBS Global Life Sciences Conference (September 22-25, 2008) in New York.

Dr. Francis Pinto, Chief Executive Officer of Pharming, will present an update of the Company and its business on Monday, September 22 at 2:30 pm Eastern Time. The presentation will be available on Pharming's website after the meeting. The conference attendees include institutional investors from the United States, Europe and Asia-Pacific. For further information on the UBS Global Life Sciences Conference, please visit

About Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, and on

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.


Carina Hamaker, Investor Voice, T: +31 (0)6 537 499 59 or T: +31 (0)71 52 47 400 Julia Philips (UK), Financial Dynamics, T: +44 (0)20 7269 7187 or T: +44 (0)7770 827 263 Samir Singh (US), Pharming Group NV, T: +1 908 720 6224 Rein Strijker, Pharming Group NV, T: +31 (0)71 52 47 400


Pharming Group N.V.

ISIN: NL0000377018

Stock Identifier: XAMS.PHARM


Verbundene Unternehmen

B&B Tools AB

ABN Newswire
ABN Newswire Diese Seite wurde besucht:  (letzten 7 Tagen: 1) (letzten 30 Tagen: 5) (seit Veröffentlichung: 581)